XNCR vs. KNSA, IRWD, PCRX, AVDL, ANIP, PRTA, ABCL, OCUL, AKRO, and IMNM
Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Kiniksa Pharmaceuticals (KNSA), Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), Avadel Pharmaceuticals (AVDL), ANI Pharmaceuticals (ANIP), Prothena (PRTA), AbCellera Biologics (ABCL), Ocular Therapeutix (OCUL), Akero Therapeutics (AKRO), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry.
Xencor (NASDAQ:XNCR) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Xencor presently has a consensus price target of $35.71, indicating a potential upside of 61.38%. Kiniksa Pharmaceuticals has a consensus price target of $28.00, indicating a potential upside of 41.92%. Given Xencor's higher probable upside, research analysts plainly believe Xencor is more favorable than Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals has a net margin of 5.11% compared to Xencor's net margin of -74.90%. Kiniksa Pharmaceuticals' return on equity of -6.12% beat Xencor's return on equity.
Xencor has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
In the previous week, Xencor and Xencor both had 1 articles in the media. Xencor's average media sentiment score of 1.89 beat Kiniksa Pharmaceuticals' score of 1.87 indicating that Xencor is being referred to more favorably in the media.
Xencor received 329 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 72.81% of users gave Xencor an outperform vote while only 63.64% of users gave Kiniksa Pharmaceuticals an outperform vote.
54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 5.0% of Xencor shares are owned by insiders. Comparatively, 54.2% of Kiniksa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Kiniksa Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Kiniksa Pharmaceuticals beats Xencor on 10 of the 17 factors compared between the two stocks.
Get Xencor News Delivered to You Automatically
Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools